The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Brain tissue responses to ischemia
Open accessAbstract
The brain is particularly vulnerable to ischemia. Complete interruption of blood flow to the brain for only 5 minutes triggers the death of vulnerable neurons in several brain regions, whereas 20–40 minutes of ischemia is required to kill cardiac myocytes or kidney cells. In part, the prominent vulnerability of brain tissue to ischemic damage reflects its high metabolic rate. Although the human brain represents only about 2.5% of body weight, it accounts for 25% of basal metabolism, a metabolic rate 3.5 times higher even than that of the brains of other primate species. In addition, central neurons have a near-exclusive dependence on glucose as an energy substrate, and brain stores of glucose or glycogen are limited. However, over the last 15 years, evidence has emerged indicating that energetics considerations and energy substrate limitations are not solely responsible for the brain’s heightened vulnerability to ischemia. Rather, it appears that the brain’s intrinsic cell-cell and intracellular signaling mechanisms, normally responsible for information processing, become harmful under ischemic conditions, hastening energy failure and enhancing the final pathways underlying ischemic cell death in all tissues, including free radical production, activation of catabolic enzymes, membrane failure, apoptosis, and inflammation. Since these common pathways are explored in other accompanying JCI Perspectives, we will emphasize the role of injury-enhancing signaling mechanisms specific to the central nervous system (CNS) and discuss potential therapeutic approaches to interrupting these mechanisms. Refinement of glutamate receptor antagonist approaches. A major limitation in past clinical trials of glutamate receptor antagonists has been dose ceilings imposed by drug side effects. Not unexpectedly, interfering with the brain’s major excitatory transmitter system can lead to alterations in motor or cognitive function (prominent with NMDA antagonists), or sedation (prominent with AMPA antagonists). It seems plausible that the therapeutic index of NMDA antagonist therapy might be improved by the utilization of subtype-selective agents, such as ifenprodil, an antagonist selective for the NR2B subtype of NMDA receptors. NR2B receptors are preferentially expressed in forebrain relative to hindbrain, so blocking these receptors may produce greater neuroprotection in forebrain with less interference with motor function than subtype-unselective NMDA antagonists. In addition, ifenprodil inhibition of NR2B receptors increases with increasing agonist stimulation, a “use dependency” that might increase drug effect at overactivated synapses relative to normal synapses (46). The neuroprotective efficacy of NMDA antagonist therapy might also be enhanced by combination with AMPA or kainate receptor antagonists, both to increase overall antiexcitotoxic efficacy on ischemic neurons, as well as specifically to extend protection to GABAergic neurons expressing Ca2+-permeable AMPA receptors, and oligodendrocytes. Indeed, failure to rescue GABAergic neurons while successfully rescuing nearby excitatory neurons might lead to an increase in local circuit excitation and seizure activity in stroke survivors. High-level pan-blockade of both NMDA and AMPA receptors could have problematic side effects, for example, respiratory depression, but these difficulties might be surmountable through the use of subtype-selective drugs. An alternative approach to blocking NMDA and AMPA receptors concurrently might be to reduce glutamate release, for example, through hypothermia or reduction of circuit excitability with GABA agonists or blockers of voltage-gated Na+ channels. Zinc-directed therapies. While current putative antiexcitotoxic therapies have focused on glutamate receptor activation and resultant Ca2+ overload, the pathological role of neuronal Zn2+ overload suggests additional targets for therapeutic intervention. Indeed, variable reduction of toxic Zn2+ influx may underlie some of the inconsistent beneficial effects of voltage-gated Ca2+-channel antagonists observed in animal models of transient global ischemia (47). Further delineation of the precise routes responsible for toxic Zn2+ may permit greater reduction in this toxic Zn2+ overload. Another possible approach would be to reduce Zn2+ release from nerve terminals. In settings where ischemia is anticipated, it may even prove possible to accomplish this via acute dietary zinc reduction, as anecdotal evidence in humans has suggested that such reduction profoundly disturbs brain function, likely due to reduction of transmitter Zn2+ release (48). Further off, one can envision strategies for modifying neuronal Zn2+ transporters to improve the extrusion or sequestration of intracellular Zn2+, or for upregulating intracellular Zn2+-binding proteins such as metallothioneins. Combination therapies. Recent implication of apoptosis in the pathogenesis of ischemic neuronal death rai
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Self-citationPreconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium.
Murry, C. E., Jennings, R. B., & Reimer, K. A. (1986) · Circulation · doi:10.1161/01.cir.74.5.1124 · Cited by 7,812
Cell Death: The Significance of Apoptosis
Wyllie, A. H., Kerr, J. F. R., & Currie, A. R. (1980) · International Review of Cytology · doi:10.1016/s0074-7696(08)62312-8 · Cited by 7,162
Pathobiology of ischaemic stroke: an integrated view
Dirnagl, U., Iadecola, C., & Moskowitz, M. A. (1999) · Trends in Neurosciences · doi:10.1016/s0166-2236(99)01401-0 · Cited by 3,943
Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene
Yang, D. D., Kuan, C.-Y., Whitmarsh, A. J., Rinócn, M., Zheng, T. S., Davis, R. J., Rakic, P., & Flavell, R. A. (1997) · Nature · doi:10.1038/39899 · Cited by 1,238
The changing landscape of ischaemic brain injury mechanisms
Lee, J.-M., Zipfel, G. J., & Choi, D. W. (1999) · Nature · doi:10.1038/399a007 · Cited by 1,102 · cited 2×
“Recent implication of apoptosis in the pathogenesis of ischemic neuronal death raises an unsettling possibility that current efforts to block NMDA receptor-mediated Ca2+ influx may go too far, achieving the desired reduction of toxic calcium overload and excitotoxicity in some neurons, but then promoting apoptosis in…”
BackgroundSelf-citation‘Ischemic tolerance’ phenomenon found in the brain
Kitagawa, K., Matsumoto, M., Tagaya, M., Hata, R., Ueda, H., Niinobe, M., Handa, N., Fukunaga, R., Kimura, K., Mikoshiba, K., et al. (1990) · Brain Research · doi:10.1016/0006-8993(90)90189-i · Cited by 1,091
Neurobiology of Zinc and Zinc-Containing Neurons
Frederickson, C. J. (1989) · International Review of Neurobiology · doi:10.1016/s0074-7742(08)60279-2 · Cited by 1,075
Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2
Bonventre, J. V., Huang, Z., Taheri, M. R., O'Leary, E., Li, E., Moskowitz, M. A., & Sapirstein, A. (1997) · Nature · doi:10.1038/37635 · Cited by 845
Dugan, L., Sensi, S., Canzoniero, L., Handran, S., Rothman, S., Lin, T., Goldberg, M., & Choi, D. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-10-06377.1995 · Cited by 772
Self-citationEnzymatic function of nitric oxide synthases
Andrew, P. (1999) · Cardiovascular Research · doi:10.1016/s0008-6363(99)00115-7 · Cited by 753
Choi, D. W., & Koh, J. Y. (1998) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.21.1.347 · Cited by 752
Self-citationRole of poly(ADP-ribose) synthetase in inflammation and ischaemia–reperfusion
Szabó, C., & Dawson, V. L. (1998) · Trends in Pharmacological Sciences · doi:10.1016/s0165-6147(98)01193-6 · Cited by 685
del Zoppo, G., Ginis, I., Hallenbeck, J. M., Iadecola, C., Wang, X., & Feuerstein, G. Z. (2000) · Brain Pathology · doi:10.1111/j.1750-3639.2000.tb00247.x · Cited by 662
Nitric Oxide Synthase in Models of Focal Ischemia
Samdani, A. F., Dawson, T. M., & Dawson, V. L. (1997) · Stroke · doi:10.1161/01.str.28.6.1283 · Cited by 656
Very Delayed Infarction after Mild Focal Cerebral Ischemia: A Role for Apoptosis?
Du, C., Hu, R., Csernansky, C. A., Hsu, C. Y., & Choi, D. W. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199603000-00003 · Cited by 600
Self-citationThe search for physiological substrates of MAP and SAP kinases in mammalian cells
COHEN, P. (1997) · Trends in Cell Biology · doi:10.1016/s0962-8924(97)01105-7 · Cited by 536
Barone, F. C., White, R. F., Spera, P. A., Ellison, J., Currie, R. W., Wang, X., & Feuerstein, G. Z. (1998) · Stroke · doi:10.1161/01.str.29.9.1937 · Cited by 486
MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia
Alessandrini, A., Namura, S., Moskowitz, M. A., & Bonventre, J. V. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12866 · Cited by 464
Caspases as treatment targets in stroke and neurodegenerative diseases
Schulz, J. B., Weller, M., & Moskowitz, M. A. (1999) · Annals of Neurology · doi:10.1002/1531-8249(199904)45:4<421::aid-ana2>3.0.co;2-q · Cited by 319
Gonzalez-Zulueta, M., Feldman, A. B., Klesse, L. J., Kalb, R. G., Dillman, J. F., Parada, L. F., Dawson, T. M., & Dawson, V. L. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.1.436 · Cited by 315
The role of protein kinase C in the regulation of ion channels and neurotransmitter release
Kaczmarek, L. K. (1987) · Trends in Neurosciences · doi:10.1016/0166-2236(87)90122-6 · Cited by 306
Tønder, N., Johansen, F. F., Frederickson, C. J., Zimmer, J., & Diemer, N. H. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90002-q · Cited by 301
Gene Expression Induced by Cerebral Ischemia: An Apoptotic Perspective
MacManus, J. P., & Linnik, M. D. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/aj.jcbfm.9590266 · Cited by 300
Henkin, R. I. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490530067006 · Cited by 280
N‐methyl‐D‐aspartate antagonists: Ready for clinical trial in brain ischemia?
Albers, G. W., Goldberg, M. P., & Choi, D. W. (1989) · Annals of Neurology · doi:10.1002/ana.410250412 · Cited by 272
Self-citationIschemic tolerance in the brain
Chen, J., & Simon, R. (1997) · Neurology · doi:10.1212/wnl.48.2.306 · Cited by 271
Kim, Y.-H., Kim, E. Y., Gwag, B. J., Sohn, S., & Koh, J.-Y. (1999) · Neuroscience · doi:10.1016/s0306-4522(98)00313-3 · Cited by 267
Six-Hour Window of Opportunity for Calpain Inhibition in Focal Cerebral Ischemia in Rats
Markgraf, C. G., Velayo, N. L., Johnson, M. P., McCarty, D. R., Medhi, S., Koehl, J. R., Chmielewski, P. A., & Linnik, M. D. (1998) · Stroke · doi:10.1161/01.str.29.1.152 · Cited by 248
Kew, J. N., Trube, G., & Kemp, J. A. (1996) · The Journal of Physiology · doi:10.1113/jphysiol.1996.sp021807 · Cited by 240
Ischemic Tolerance in Murine Cortical Cell Culture: Critical Role for NMDA Receptors
Grabb, M. C., & Choi, D. W. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-05-01657.1999 · Cited by 237
Self-citationZHAO, Q., PAHLMARK, K., SMITH, M. ‐., & SIESJÖ, B. K. (1994) · Acta Physiologica Scandinavica · doi:10.1111/j.1748-1716.1994.tb09816.x · Cited by 198
Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
von Lubitz, D. K. J. E. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00135-1 · Cited by 175
Ma, J., Endres, M., & Moskowitz, M. A. (1998) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0701871 · Cited by 163
A “calcium set-point hypothesis” of neuronal dependence on neurotrophic factor
Johnson, E. M., Koike, T., & Franklin, J. (1992) · Experimental Neurology · doi:10.1016/0014-4886(92)90242-i · Cited by 161
Hara, H., Onodera, H., Yoshidomi, M., Matsuda, Y., & Kogure, K. (1990) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1990.117 · Cited by 157
Do NMDA antagonists protect against cerebral ischemia: are clinical trials warranted?
Buchan, A. M. (1990) · PubMed · Cited by 153
Respiratory Chain Inhibition Induces Tolerance to Focal Cerebral Ischemia
Wiegand, F., Liao, W., Busch, C., Castell, S., Knapp, F., Lindauer, U., Megow, D., Meisel, A., Redetzky, A., Ruscher, K., et al. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199911000-00007 · Cited by 144
Extracellular neurotransmitter changes in cerebral ischaemia.
Obrenovitch, T. P., & Richards, D. A. (1995) · PubMed · Cited by 124
Protective responses in the ischemic myocardium
Williams, R. S., & Benjamin, I. J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11205 · Cited by 123
Kerchner, G. A., Canzoniero, L. M. T., Yu, S. P., Ling, C., & Choi, D. W. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00039.x · Cited by 102
Self-citationNagayama, M., Zhang, F., & Iadecola, C. (1998) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199810000-00007 · Cited by 97
Du, C., Hu, R., Csernansky, C. A., Liu, X.-Z., Hsu, C. Y., & Choi, D. W. (1996) · Brain Research · doi:10.1016/0006-8993(96)00162-x · Cited by 74
Self-citationDouen, A. G., Akiyama, K., Hogan, M. J., Wang, F., Dong, L., Chow, A. K., & Hakim, A. M. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750812.x · Cited by 71
Adenosine and cerebral ischemia: therapeutic future or death of a brave concept?
Lubitz, D. K. J. E. V. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00788-2 · Cited by 62
Sugino, T., Nozaki, K., & Hashimoto, N. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(99)00906-4 · Cited by 47
Neurotrophin-mediated potentiation of neuronal injury
Behrens, M. M., Strasser, U., Lobner, D., & Dugan, L. L. (1999) · Microscopy Research and Technique · doi:10.1002/(sici)1097-0029(19990515/01)45:4/5<276::aid-jemt11>3.0.co;2-4 · Cited by 37
Cited by
Cell Biology of Ischemia/Reperfusion Injury
(2012) · International Review of Cell and Molecular Biology · doi:10.1016/b978-0-12-394309-5.00006-7 · Cited by 2,178
Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052
Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions
Qin, C., Yang, S., Chu, Y.-H., Zhang, H., Pang, X.-W., Chen, L., Zhou, L.-Q., Chen, M., Tian, D.-S., & Wang, W. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01064-1 · Cited by 939
Mechanisms of neuronal cell death in ischemic stroke and their therapeutic implications
Tuo, Q., Zhang, S., & Lei, P. (2022) · Medicinal Research Reviews · doi:10.1002/med.21817 · Cited by 728
Kalogeris, T., Baines, C. P., Krenz, M., & Korthuis, R. J. (2016) · Comprehensive Physiology · doi:10.1002/cphy.c160006 · Cited by 718
Metadata
- Authors
- Lee, J.-M., Grabb, M. C., Zipfel, G. J., & Choi, D. W.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-09-15
- Volume
- 106
- Issue
- 6
- Pages
- 723-731
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2055767424
- Cited by
- 548
- References
- 47
- FWCI
- 14.42
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.